Key highlights
- Cook Medical becomes a non-exclusive distributor of TULSA-PRO for specific iMRI suite equipment
- Agreement features an initial five-year term starting after necessary FDA clearance
- Profound retains direct control over the sale of single-use disposables and maintenance services
- The partnership requires FDA clearance by April 30, 2027, to avoid potential termination
- Profound reported record quarterly purchase orders exceeding $7.0 million in Q2 2026
What Is the Partnership?
Profound Medical (U.S.) Inc. has finalized a Supply and Distribution Agreement with Cook Medical Holdings LLC to serve as a non-exclusive distributor for the TULSA-PRO system in the United States. Under the contract, Cook is authorized to sell the system specifically for use within its proprietary Copernicus intraoperative MRI suites. While Cook will purchase the capital equipment at a set transfer price for resale, Profound maintains the exclusive right to provide single-use disposables and multi-year service contracts. The arrangement is contingent on receiving FDA clearance for the combined hardware use by April 30, 2027, after which the initial five-year term officially commences.
Partner Profile
Cook Medical Holdings LLC is a global medical device manufacturer, with its iMRI Division specializing in real-time MRI-guided interventions that eliminate the need for ionizing radiation. The company’s Copernicus program acts as a comprehensive turnkey solution for healthcare providers, offering the design, implementation, and clinical training necessary to establish dedicated iMRI programs. By integrating TULSA-PRO into this framework, Cook provides urologists with an incision-free prostate therapy that works alongside high-field MRI scanners. This collaboration allows hospitals to adopt sophisticated MRI-guided therapies through a single vendor relationship while utilizing Cook’s established presence in the urological and interventional radiology sectors.
What It Unlocks
- Immediate access to Cook Medical’s specialized urology sales team and established hospital relationships
- Integration into a broader procedural ecosystem that includes Siemens Healthineers imaging technology
- A secondary capital sales channel to monetize a qualified pipeline currently valued at $70 million
- Geographic scale across all U.S. territories without increasing direct commercial overhead
- Synergy between new capital system placements and Profound’s core recurring revenue streams
Financial Context
Profound Medical continues to see strong commercial interest, recently reiterating its full-year 2026 revenue guidance of approximately $25.0 million. Achieving this target would represent a 56% increase over the prior year. The company’s current financial position is supported by a gross margin target of 70% or higher, reflecting the shift toward recurring disposable sales. With a market capitalization of roughly $255.4 million and a recent stock price of $6.99, the company is leveraging partnerships like the Cook Medical agreement to accelerate the adoption of its TULSA procedure. This strategy aims to convert its growing order book into long-term service and treatment kit revenue.
Up 5.0% since our story on 3 Nov: $6.99 when we broke it → $7.34 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $5.86 |
|---|---|
| 20 Oct | $5.92 |
| 21 Oct | $5.69 |
| 22 Oct | $5.76 |
| 23 Oct | $5.56 |
| 26 Oct | $5.55 |
| 27 Oct | $5.64 |
| 28 Oct | $5.78 |
| 29 Oct | $5.86 |
| 30 Oct | $6.57 |
| 2 Nov | $6.73 |
| 3 Nov | $6.99 |
| 4 Nov | $7.16 |
| 5 Nov | $6.88 |
| 6 Nov | $7.21 |
| 9 Nov | $7.34 |
| 10 Nov | $7.68 |
| 11 Nov | $7.85 |
| 12 Nov | $7.44 |
| 13 Nov | $7.42 |
| 16 Nov | $7.34 |
| Date | Announcement | Amount |
|---|---|---|
| 30 Oct 2026 | Supply and distribution agreement with Cook Medical's iMRI Division to expand U.S. sales of the TULSA-PRO system via Cook's Copernicus programSource: ir.profoundmedical.com | – |
| 09 Oct 2026 | Co-education agreement with Telix Pharmaceuticals to advance PSMA-informed prostate care combining TULSA-PRO and PSMA-PET imaging technologiesSource: ir.profoundmedical.com | – |
| 12 Nov 2025 | Exclusive distribution and supply agreement with Getz Healthcare for TULSA-PRO in Australia and New ZealandSource: globenewswire.com | – |
| 11 Nov 2025 | Exclusive distribution and supply agreement with Al Faisaliah Medical Systems Co. for TULSA-PRO and Sonalleve in Saudi ArabiaSource: ir.profoundmedical.com | – |
| 10 Nov 2025 | Agreement with Knight Therapeutics to regain exclusive Canadian commercial distribution rights for TULSA-PROSource: globenewswire.com | $0.1 Million |
| 02 Dec 2024 | Definitive co-sales and co-marketing agreement with Siemens Healthineers to commercialize MRI-guided prostate therapy combining TULSA-PRO and Magnetom Free.MaxSource: globenewswire.com | – |
Management commentary
“This agreement broadens our commercial reach by making TULSA-PRO part of a comprehensive offering for hospitals investing in MRI-guided intervention.”
“Through our Copernicus™ program we help hospitals plan, build, and sustain iMRI programs, and TULSA-PRO gives those hospitals an FDA-cleared, incision-free prostate therapy to offer patients who want to return to their daily lives sooner.”
| Share price | $6.99 |
|---|---|
| Market cap | $255M |
| Revenue (annual) | $16M |
| 1-month price change | +19.69% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Profound Medical Corp. announcing a supply and distribution agreement with Cook Medical Holdings LLC.
Track Profound Medical Corp. live
Get the next Profound Medical Corp. SEC filing seconds after it lands.





